Jonathan C Man, 5610 Rollins Ct, Cambridge, MA 02139

D659819, May 15, 2012

Dec 18, 2009

29/352274

David A. Edwards - Boston MA, US
Jóse Sanchez - Paris, FR
Jonathan Man - Bellevue WA, US
Jonathan Jacques Kamler - Jamaica NY, US

Breathable Foods, Inc. - Cambridge MA

2902

D24110

8187637, May 29, 2012

Mar 6, 2007

11/714999

David A. Edwards - Boston MA, US
Jonathan C. Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Canton MA, US

Pulmatrix, Inc. - Lexington MA

A61K 9/00
A61K 9/08
A61K 9/10
A61K 9/12
A61K 9/14

424489, 424 46

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

8591866, Nov 26, 2013

Apr 25, 2012

13/455585

David A. Edwards - Boston MA, US
Jonathan Chun-Wah Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Medfield MA, US

Pulmatrix, Inc. - Lexington MA

A61K 9/00
A61K 9/12
A61K 9/14

424 46, 424489

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

8627821, Jan 14, 2014

Jul 10, 2007

11/827031

David A. Edwards - Boston MA, US
Mark J. Gabrielson - Ridgefield CT, US
Robert William Clarke - Canton MA, US
Wesley H. Dehaan - Chelmsford MA, US
Matthew Frederick Brande - Bristol CT, US
Jonathan Chun-Wah Man - Bellevue WA, US

Pulmatrix, Inc. - Lexington MA

A62B 7/00
A61M 15/00
A61M 16/00
F16K 31/02
A62B 9/00
A61B 5/08

12820522, 12820527, 12820024, 12820222, 12820421, 12820422, 12820423, 12820523, 600529, 600530, 600531, 600532, 600533, 600534, 600535, 600536, 600537, 600538, 600539, 600540, 600541, 600542, 600543

Methods and devices to determine rate of particle production and the size range for the particles produced for an individual are described herein. The device () contains a mouthpiece (), a filter (), a low resistance one-way valve (), a particle counter () and a computer (). Optionally, the device also contains a gas flow meter (). The data obtained using the device can be used to determine if a formulation for reducing particle exhalation should be administered to an individual.

2005020, Sep 22, 2005

Nov 17, 2004

10/990996

David Edwards - Boston MA, US
Jonathan Man - Cambridge MA, US
Jeffrey Katstra - Watertown MA, US
Robert Clarke - Canton MA, US

A61L009/04
A61K048/00
A61K038/17
A61K031/70
A61K031/715

424044000, 514002000, 514044000, 514054000, 514561000

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

2012011, May 10, 2012

Dec 3, 2009

13/132469

David A. Edwards - Boston MA, US
Jonathan Man - Bellevue WA, US
Jonathan Jacques Kamler - Jamaica NY, US
Jose Sanchez - Paris, FR
Marc Bretillot - Paris, FR

B65D 83/14
A23P 1/16

426116, 426106, 222635

Aerosolized food products in a determined particle size range are suspended in the air and deposited in the mouth without easily entering into the respiratory tract. An apparatus incorporating an aerosol generating device and food products can allow for the aerosolization of the food products and the delivery thereof in a manner suitable for inhalation or deposition and subsequent ingestion. The food delivery apparatus represents a novel means for delivering food to the mouths of humans and animals. Indeed, the apparatus of the invention is designed to produce, transport, and direct aerosolized food particles in a determined size range, suspended in air, to be deposited in the mouth without substantial exposure or entry into the respiratory tract.

D631538, Jan 25, 2011

Apr 3, 2009

29/334903

David A. Edwards - Boston MA, US
Jonathan Jacques Kamler - Jamaica NY, US
Jonathan Man - Bellevue WA, US
Jose Sanchez - Paris, FR

Le Labogroup SAS - Paris

2902

D241105

2015007, Mar 19, 2015

Oct 21, 2013

14/058852

- Lexington MA, US
Jonathan Chun-Wah MAN - Cambridge MA, US
Jeffrey P. KATSTRA - Watertown MA, US
Robert W. CLARKE - Medfield MA, US

PULMATRIX, INC. - Lexington MA

A61K 47/02
A61K 9/00

424489, 514769

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.